Understanding AS01 Adjuvant Mode of Action in Vaccines
The use of adjuvant is required in some vaccine formulations to provide help to the antigen in order to enhance the immune response. The use of adjuvants in certain types of vaccine is inevitable to elicit a strong and targeted immune response.
Following induction of different adjuvants into vaccines in the 90’s, the need to combine adjuvants in so called adjuvant systems to enhance immunogenicity became apparent. The following video will highlight the mode of action of one specific adjuvants system: AS01:
References
Didierlaurent AM, Collignon C, Bourguignon P, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol 2014; 193:1920–1930. Leo O, Cunningham A & Stern PL. Vaccine Immunology. Understanding Modern Vaccines: Perspectives in Vaccinology. Elsevier vol.2011; 25–59. Garcon N, Lerous-Roels G & Cheng WF. Vaccine adjuvants. Understanding Modern Vaccines: Perspectives in Vaccinology. vol.2016; 89–113. Dendouga N, Fochesato M, Lockman L, et al. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine 2012; 30:3126–3135. Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327:656–661. Rezk SA & Weis L. Lymph Nodes. http://www.els.net [doi: 10.1002/9780470015902.a0000525.pub3 .2015. John Wiley & sons.
Material supplied by the above-country business unit to LOCs for localisation must be subject to local Medical and/or Regulatory review and approval prior to use and/or external distribution.
LOCs to insert local adverse events reporting procedure.
© 2022 GSK group of companies or its licensor. GlaxoSmithKline Biologicals SA. Rixensart, Belgium.
NX-GBL-GVX-WCNT-220016 | August 2022